BMO Capital Downgrades Mirati Therapeutics (MRTX) to Market Perform
Tweet Send to a Friend
(Updated - December 8, 2022 5:28 AM EST)
BMO Capital analyst Evan David Seigerman downgraded Mirati Therapeutics (NASDAQ: MRTX) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
BMO Capital analyst Evan David Seigerman downgraded Mirati Therapeutics (NASDAQ: MRTX) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
